Shareholders of LakeShore Biopharma Co., Ltd (OTCPK: LSBCF; OTCPK: LSBWF) have voted in favor of the proposed merger with Oceanpine Skyline Inc., setting the stage for the company to go private. At an extraordinary general meeting held on June 19, 2026, approximately 92.3% of the company's outstanding ordinary shares were represented, and about 86.2% of the votes cast supported the merger agreement, as announced in a press release on NewMediaWire.
The merger agreement, originally dated November 4, 2025, and amended on April 29, 2026, involves LakeShore Biopharma, Parent company Oceanpine Skyline Inc., and its wholly owned subsidiary Oceanpine Merger Sub Inc. Upon completion, Merger Sub will merge into LakeShore Biopharma, which will continue as the surviving entity and become a wholly owned subsidiary of Parent. The company will then cease to be publicly traded, with its shares and warrants delisted from the OTC Pink tier of the OTC Markets and deregistered under the Securities Exchange Act of 1934.
This move marks a significant transition for LakeShore Biopharma, formerly known as YS Biopharma, which has been focused on developing vaccines and therapeutic biologics for infectious diseases and cancer. The company's proprietary PIKA® immunomodulating technology platform underpins its pipeline, which includes candidates targeting rabies, hepatitis B, influenza, and other viral infections. Operating in China, Singapore, and the Philippines, the company is led by a management team with deep local and global biopharmaceutical expertise.
The approval of the merger underscores shareholder confidence in the strategic direction, though the transaction remains subject to customary closing conditions. The company stated it will work diligently to satisfy these conditions and complete the merger in due course. The transition to a private structure could allow LakeShore Biopharma to operate with greater flexibility, away from the quarterly earnings pressures of public markets, potentially accelerating its research and development efforts.
As the company prepares for this change, it continues to navigate risks inherent in its business, including the possibility that the merger may not close if conditions are not met or waived. Other uncertainties include financing availability and broader economic conditions. Forward-looking statements in the announcement highlight these risks, as detailed in filings with the U.S. Securities and Exchange Commission, including the Schedule 13E-3 and proxy statement.
For investors, the shareholder vote represents a key milestone in the privatization process. Upon completion, LakeShore Biopharma will join the ranks of biotech firms that have chosen to operate outside the public eye, focusing on long-term value creation. The company's future developments will be closely watched by stakeholders, particularly as it advances its vaccine and therapeutic programs.
